DE69514234T2 - Oberflächenlokalisierte expression von enzymen in gengesteuerter prodrugtherapie - Google Patents
Oberflächenlokalisierte expression von enzymen in gengesteuerter prodrugtherapieInfo
- Publication number
- DE69514234T2 DE69514234T2 DE69514234T DE69514234T DE69514234T2 DE 69514234 T2 DE69514234 T2 DE 69514234T2 DE 69514234 T DE69514234 T DE 69514234T DE 69514234 T DE69514234 T DE 69514234T DE 69514234 T2 DE69514234 T2 DE 69514234T2
- Authority
- DE
- Germany
- Prior art keywords
- enzymes
- controlled
- general
- prodrug therapy
- localized expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9415167A GB9415167D0 (en) | 1994-07-27 | 1994-07-27 | Improvements relating to cancer therapy |
PCT/GB1995/001782 WO1996003515A2 (en) | 1994-07-27 | 1995-07-27 | Surface expression of enzyme in gene directed prodrug therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69514234D1 DE69514234D1 (de) | 2000-02-03 |
DE69514234T2 true DE69514234T2 (de) | 2000-07-13 |
Family
ID=10758973
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69535916T Expired - Lifetime DE69535916D1 (de) | 1994-07-27 | 1995-07-27 | Oberflächenlokalisierte Expression von Enzymen in gengesteuerter Prodrugtherapie |
DE69534599T Expired - Lifetime DE69534599T2 (de) | 1994-07-27 | 1995-07-27 | Intrazellulare expression von carboxypeptidase g2 in enzyme-prodrug-therapie |
DE69514234T Expired - Lifetime DE69514234T2 (de) | 1994-07-27 | 1995-07-27 | Oberflächenlokalisierte expression von enzymen in gengesteuerter prodrugtherapie |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69535916T Expired - Lifetime DE69535916D1 (de) | 1994-07-27 | 1995-07-27 | Oberflächenlokalisierte Expression von Enzymen in gengesteuerter Prodrugtherapie |
DE69534599T Expired - Lifetime DE69534599T2 (de) | 1994-07-27 | 1995-07-27 | Intrazellulare expression von carboxypeptidase g2 in enzyme-prodrug-therapie |
Country Status (15)
Country | Link |
---|---|
US (2) | US6025340A (de) |
EP (3) | EP0774005B1 (de) |
JP (3) | JPH10505335A (de) |
AT (3) | ATE188256T1 (de) |
AU (2) | AU693584B2 (de) |
CA (2) | CA2196052A1 (de) |
DE (3) | DE69535916D1 (de) |
DK (1) | DK0774005T3 (de) |
ES (1) | ES2143641T3 (de) |
GB (1) | GB9415167D0 (de) |
GR (1) | GR3032744T3 (de) |
NZ (2) | NZ290448A (de) |
PT (1) | PT774005E (de) |
WO (2) | WO1996003151A2 (de) |
ZA (2) | ZA956263B (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE37736E1 (en) | 1992-05-05 | 2002-06-11 | Automotive Technologies International Inc. | Vehicle occupant position and velocity sensor |
GB9709421D0 (en) | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
CA2211293A1 (en) * | 1997-07-23 | 1999-01-23 | Immunova Ltee | Recombinant lysostaphin analogs |
AU9016998A (en) | 1997-08-08 | 1999-03-01 | Newbiotics, Inc. | Methods and compositions for overcoming resistance to biologic and chemotherapy |
EP1240922B1 (de) * | 1997-08-08 | 2008-11-12 | Celmed Oncology (USA), Inc. | Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden |
US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
CN1192102C (zh) * | 1998-01-23 | 2005-03-09 | 新生物生物公司 | 酶催化的治疗剂 |
US6410328B1 (en) | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
WO1999039741A2 (en) | 1998-02-03 | 1999-08-12 | Inex Pharmaceuticals Corporation | Systemic delivery of serum stable plasmid lipid particles for cancer therapy |
JP2002505341A (ja) * | 1998-03-06 | 2002-02-19 | オックスフォード バイオメディカ(ユーケイ)リミテッド | プロドラッグの活性化の増強 |
GB9907414D0 (en) | 1999-03-31 | 1999-05-26 | Cancer Res Campaign Tech | Improvements relating to prodrugs |
EP1173225A2 (de) * | 1999-04-30 | 2002-01-23 | Karsten Brand | Mittel zur gentherapie und zur prävention von metastasen bzw. zur gentherapie von tumoren |
GB9910077D0 (en) | 1999-05-01 | 1999-06-30 | Univ Manchester | Chemical compounds |
DE19928342A1 (de) * | 1999-06-21 | 2000-12-28 | Deutsches Krebsforsch | Vektoren zur gentherapeutischen Tumorbehandlung |
US6656917B1 (en) * | 1999-06-30 | 2003-12-02 | Marker Gene Technologies, Inc. | Compositions and methods for targeted enzymatic release of cell regulatory compounds |
JP2003525866A (ja) * | 1999-07-22 | 2003-09-02 | ニューバイオティックス インコーポレイテッド | 治療抵抗性腫瘍を処置するための方法 |
US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
GB0011060D0 (en) * | 2000-05-08 | 2000-06-28 | Cancer Res Campaign Tech | Improvements relating to gene directed enzyme prodrug therapy |
US6656718B2 (en) | 2000-07-07 | 2003-12-02 | Cancer Research Technology Limited | Modified carboxypeptidase enzymes and their use |
US7138388B2 (en) | 2001-01-19 | 2006-11-21 | Celmed Oncology (Usa), Inc. | Methods to treat autoimmune and inflammatory conditions |
GB0102239D0 (en) | 2001-01-29 | 2001-03-14 | Cancer Res Ventures Ltd | Methods of chemical synthisis |
BR0312692A (pt) | 2002-07-15 | 2007-06-26 | Univ Texas | anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer |
GB0220319D0 (en) | 2002-09-02 | 2002-10-09 | Cancer Res Campaign Tech | Enzyme activated self-immolative nitrogen mustard drugs |
US20050107320A1 (en) * | 2003-01-30 | 2005-05-19 | Matthew During | Methods and compositions for use in interventional pharmacogenomics |
GB0517957D0 (en) | 2005-09-03 | 2005-10-12 | Morvus Technology Ltd | Method of combating infection |
GB0526552D0 (en) | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
GB2442202A (en) | 2006-09-30 | 2008-04-02 | Morvus Technology Ltd | Vermin poison |
JP5809415B2 (ja) | 2007-11-09 | 2015-11-10 | ペレグリン ファーマシューティカルズ,インコーポレーテッド | 抗vegf抗体の組成物および方法 |
ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
GB201310917D0 (en) * | 2013-06-19 | 2013-07-31 | Cancer Res Inst Royal | Vaccinia virus for gene-directed enzyme prodrug therapy |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308483D0 (en) * | 1983-03-28 | 1983-05-05 | Health Lab Service Board | Secretion of gene products |
US4935352A (en) * | 1985-10-21 | 1990-06-19 | Takeda Chemical Industries, Ltd. | Expression vector for animal cell line and use thereof |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
GB8809616D0 (en) | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
GB8820850D0 (en) | 1988-09-05 | 1988-10-05 | Cancer Res Campaign Tech | Improvements relating to pro-drugs |
EP0387380A1 (de) * | 1989-03-17 | 1990-09-19 | BEHRINGWERKE Aktiengesellschaft | Mutanten von Plasminogenaktivator aus Urin, ihre Herstellung und Verwendung |
US5665543A (en) * | 1989-07-18 | 1997-09-09 | Oncogene Science, Inc. | Method of discovering chemicals capable of functioning as gene expression modulators |
GB8919607D0 (en) * | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
GB8920011D0 (en) | 1989-09-05 | 1989-10-18 | Mann J | New route of synthesis for tertiary butyl esters |
US5223408A (en) * | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
AU681337B2 (en) | 1991-10-23 | 1997-08-28 | Cancer Research Campaign Technology Limited | Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form |
GB9314960D0 (en) * | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
JPH09500125A (ja) | 1993-07-15 | 1997-01-07 | キャンサー リサーチ キャンペーン テクノロジー リミテッド | タンパク質チロシンキナーゼインヒビターのプロドラッグ |
GB9315494D0 (en) | 1993-07-27 | 1993-09-08 | Springer Caroline | Improvements relating to prodrugs |
GB9423367D0 (en) * | 1994-11-18 | 1995-01-11 | Wellcome Found | Enzyme prodrug therapy |
-
1994
- 1994-07-27 GB GB9415167A patent/GB9415167D0/en active Pending
-
1995
- 1995-07-27 AT AT95927025T patent/ATE188256T1/de not_active IP Right Cessation
- 1995-07-27 WO PCT/GB1995/001783 patent/WO1996003151A2/en active IP Right Grant
- 1995-07-27 NZ NZ290448A patent/NZ290448A/en unknown
- 1995-07-27 AU AU31190/95A patent/AU693584B2/en not_active Ceased
- 1995-07-27 DE DE69535916T patent/DE69535916D1/de not_active Expired - Lifetime
- 1995-07-27 AT AT95927026T patent/ATE308999T1/de not_active IP Right Cessation
- 1995-07-27 NZ NZ290449A patent/NZ290449A/en unknown
- 1995-07-27 EP EP95927025A patent/EP0774005B1/de not_active Expired - Lifetime
- 1995-07-27 DK DK95927025T patent/DK0774005T3/da active
- 1995-07-27 AT AT98123229T patent/ATE423208T1/de not_active IP Right Cessation
- 1995-07-27 JP JP8505599A patent/JPH10505335A/ja active Pending
- 1995-07-27 WO PCT/GB1995/001782 patent/WO1996003515A2/en active IP Right Grant
- 1995-07-27 EP EP95927026A patent/EP0772455B1/de not_active Expired - Lifetime
- 1995-07-27 EP EP98123229A patent/EP0919622B1/de not_active Expired - Lifetime
- 1995-07-27 DE DE69534599T patent/DE69534599T2/de not_active Expired - Lifetime
- 1995-07-27 AU AU31191/95A patent/AU712383B2/en not_active Ceased
- 1995-07-27 US US08/776,251 patent/US6025340A/en not_active Expired - Lifetime
- 1995-07-27 CA CA002196052A patent/CA2196052A1/en not_active Abandoned
- 1995-07-27 ZA ZA956263A patent/ZA956263B/xx unknown
- 1995-07-27 US US08/776,246 patent/US6004550A/en not_active Expired - Lifetime
- 1995-07-27 ES ES95927025T patent/ES2143641T3/es not_active Expired - Lifetime
- 1995-07-27 JP JP50559896A patent/JP3747290B2/ja not_active Expired - Lifetime
- 1995-07-27 CA CA002196051A patent/CA2196051A1/en not_active Abandoned
- 1995-07-27 ZA ZA956264A patent/ZA956264B/xx unknown
- 1995-07-27 PT PT95927025T patent/PT774005E/pt unknown
- 1995-07-27 DE DE69514234T patent/DE69514234T2/de not_active Expired - Lifetime
-
2000
- 2000-02-23 GR GR20000400444T patent/GR3032744T3/el not_active IP Right Cessation
-
2005
- 2005-08-15 JP JP2005235444A patent/JP2006042821A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69514234D1 (de) | Oberflächenlokalisierte expression von enzymen in gengesteuerter prodrugtherapie | |
AU3649397A (en) | Precise efficacy assay methods for active agents including chemotherapeutic agents | |
AU4186199A (en) | Method of enhancing lysosomal alpha-galactosidase a | |
DK314989A (da) | Fremgangsmaade til fremstilling af optisk aktive alfa-substituerede organiske syrer, samt mikroorganismer og enzymer anvendelige ved fremgangsmaaden | |
IL181695A0 (en) | Methods for cultivating cells and propagating viruses | |
ZA906531B (en) | Substituted n-(quinolin-2-yl-methoxy)benzyl-sulphonyl-ureas | |
GB9601640D0 (en) | Ligand directed enzyme prodrug therapy | |
DE69022778D1 (de) | Zellkultursubstrat, Bioreaktor mit Zellkultursubstrat und therapeutische Vorrichtung vom extrakorporalen Umlauftyp. | |
EP0373107A3 (de) | Benutzung von Enzymen von Aureobasidium Pullulans für das Bleichen von Zellstoff | |
SE0103276L (sv) | Anordning för administrering av salva till en hudyta | |
AU7037987A (en) | Oxygen generating herbicides synergized with detoxifying enzyme inhibitor | |
WO1998024482A3 (de) | Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung | |
GR3003950T3 (de) | ||
PT980379E (pt) | Oligonucleotidos quimericos e sua utilizacao | |
DE69825307D1 (de) | Verwendung von protein h als zytostattischer wirkstoff | |
IL128768A0 (en) | Transdermal therapeutic system containing oestriol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |